Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors
INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) faced an elevated risk for severe COVID-19 outcomes and were prioritized for early vaccination. However, immune responses to SARS-CoV-2 vaccines remain poorly characterized in this group, especially in patients receiving immune checkpoint inhibitor PD-1/PDL-1 (ICI) therapy.MATERIALS AND METHODS: In this prospective observational study,
